A detailed history of Principal Financial Group Inc transactions in Biogen Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 168,631 shares of BIIB stock, worth $29.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
168,631
Previous 163,361 3.23%
Holding current value
$29.3 Million
Previous $37.9 Million 13.69%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$189.07 - $236.8 $996,398 - $1.25 Million
5,270 Added 3.23%
168,631 $32.7 Million
Q2 2024

Jul 29, 2024

SELL
$190.52 - $236.72 $617,475 - $767,209
-3,241 Reduced 1.95%
163,361 $37.9 Million
Q1 2024

Apr 29, 2024

BUY
$212.02 - $267.71 $438,669 - $553,891
2,069 Added 1.26%
166,602 $35.9 Million
Q4 2023

Feb 07, 2024

SELL
$222.59 - $267.94 $699,377 - $841,867
-3,142 Reduced 1.87%
164,533 $42.6 Million
Q3 2023

Nov 02, 2023

SELL
$253.3 - $285.89 $642,115 - $724,731
-2,535 Reduced 1.49%
167,675 $43.1 Million
Q2 2023

Aug 07, 2023

SELL
$275.25 - $318.06 $1.7 Million - $1.96 Million
-6,167 Reduced 3.5%
170,210 $48.5 Million
Q1 2023

May 09, 2023

BUY
$256.56 - $292.34 $895,394 - $1.02 Million
3,490 Added 2.02%
176,377 $49 Million
Q4 2022

Feb 09, 2023

SELL
$252.44 - $306.72 $1.98 Million - $2.41 Million
-7,845 Reduced 4.34%
172,887 $47.9 Million
Q3 2022

Nov 09, 2022

SELL
$194.69 - $268.46 $693,680 - $956,522
-3,563 Reduced 1.93%
180,732 $48.3 Million
Q2 2022

Aug 10, 2022

BUY
$187.54 - $223.02 $2.56 Million - $3.05 Million
13,659 Added 8.0%
184,295 $37.6 Million
Q1 2022

May 09, 2022

SELL
$193.77 - $244.14 $373,201 - $470,213
-1,926 Reduced 1.12%
170,636 $35.9 Million
Q4 2021

Feb 09, 2022

SELL
$223.92 - $287.77 $1.56 Million - $2 Million
-6,952 Reduced 3.87%
172,562 $41.4 Million
Q3 2021

Nov 09, 2021

BUY
$282.99 - $369.05 $158,757 - $207,037
561 Added 0.31%
179,514 $50.8 Million
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $415,695 - $665,609
-1,605 Reduced 0.89%
178,953 $62 Million
Q1 2021

May 10, 2021

SELL
$242.95 - $284.63 $4.33 Million - $5.08 Million
-17,832 Reduced 8.99%
180,558 $50.5 Million
Q4 2020

Feb 08, 2021

SELL
$236.26 - $355.63 $4.78 Million - $7.2 Million
-20,248 Reduced 9.26%
198,390 $48.6 Million
Q3 2020

Nov 06, 2020

SELL
$264.77 - $305.71 $5.25 Million - $6.07 Million
-19,843 Reduced 8.32%
218,638 $62 Million
Q2 2020

Aug 05, 2020

SELL
$258.66 - $342.55 $3.91 Million - $5.18 Million
-15,121 Reduced 5.96%
238,481 $63.8 Million
Q1 2020

May 12, 2020

SELL
$268.85 - $341.04 $5.17 Million - $6.55 Million
-19,219 Reduced 7.04%
253,602 $80.2 Million
Q4 2019

Feb 05, 2020

SELL
$220.06 - $304.07 $2.95 Million - $4.08 Million
-13,414 Reduced 4.69%
272,821 $81 Million
Q3 2019

Nov 13, 2019

SELL
$217.44 - $243.88 $3.03 Million - $3.39 Million
-13,919 Reduced 4.64%
286,235 $66.6 Million
Q2 2019

Aug 12, 2019

SELL
$219.29 - $241.72 $10.1 Million - $11.1 Million
-45,845 Reduced 13.25%
300,154 $70.2 Million
Q1 2019

May 10, 2019

SELL
$216.71 - $338.96 $17.9 Million - $28 Million
-82,647 Reduced 19.28%
345,999 $81.8 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $4.25 Million - $5.39 Million
-15,271 Reduced 3.44%
428,646 $129 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $10.9 Million - $14.3 Million
37,205 Added 9.15%
443,917 $157 Million
Q2 2018

Aug 13, 2018

SELL
$257.52 - $306.91 $460,445 - $548,755
-1,788 Reduced 0.44%
406,712 $0
Q1 2018

May 14, 2018

SELL
$260.13 - $367.91 $6.99 Million - $9.88 Million
-26,861 Reduced 6.17%
408,500 $112 Million
Q4 2017

Feb 13, 2018

SELL
$307.64 - $344.58 $5.28 Million - $5.92 Million
-17,175 Reduced 3.8%
435,361 $139 Million
Q3 2017

Nov 02, 2017

BUY
$281.15 - $329.69 $127 Million - $149 Million
452,536
452,536 $142 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.